Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8266 to 8280 of 8943 results

  1. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued Reference number: GID-TAG439

    Technology appraisal guidance
    Discontinued

  2. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  3. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued Reference number: GID-TAG444

    Technology appraisal guidance
    Discontinued

  4. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  5. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  6. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  7. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  8. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  9. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued Reference number: GID-TA10110

    Technology appraisal guidance
    Discontinued

  11. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued Reference number: GID-TA10126

    Technology appraisal guidance
    Discontinued

  12. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  13. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  14. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued Reference number: GID-TA10138

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued Reference number: GID-TA10140

    Technology appraisal guidance
    Discontinued